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BACKGROUND
Surgical intervention is needed in some cases of spontaneous abortion to remove 
retained products of conception. Antibiotic prophylaxis may reduce the risk of 
pelvic infection, which is an important complication of this surgery, particularly 
in low-resource countries.
METHODS
We conducted a double-blind, placebo-controlled, randomized trial investigating 
whether antibiotic prophylaxis before surgery to complete a spontaneous abortion 
would reduce pelvic infection among women and adolescents in low-resource 
countries. We randomly assigned patients to a single preoperative dose of 400 mg 
of oral doxycycline and 400 mg of oral metronidazole or identical placebos. The 
primary outcome was pelvic infection within 14 days after surgery. Pelvic infection 
was defined by the presence of two or more of four clinical features (purulent 
vaginal discharge, pyrexia, uterine tenderness, and leukocytosis) or by the pres-
ence of one of these features and the clinically identified need to administer anti-
biotics. The definition of pelvic infection was changed before the unblinding of 
the data; the original strict definition was two or more of the clinical features, 
without reference to the administration of antibiotics.
RESULTS
We enrolled 3412 patients in Malawi, Pakistan, Tanzania, and Uganda. A total of 
1705 patients were assigned to receive antibiotics and 1707 to receive placebo. The 
risk of pelvic infection was 4.1% (68 of 1676 pregnancies) in the antibiotics group 
and 5.3% (90 of 1684 pregnancies) in the placebo group (risk ratio, 0.77; 95% 
confidence interval [CI], 0.56 to 1.04; P = 0.09). Pelvic infection according to origi-
nal strict criteria was diagnosed in 1.5% (26 of 1700 pregnancies) and 2.6% (44 of 
1704 pregnancies), respectively (risk ratio, 0.60; 95% CI, 0.37 to 0.96). There were 
no significant between-group differences in adverse events.
CONCLUSIONS
Antibiotic prophylaxis before miscarriage surgery did not result in a significantly 
lower risk of pelvic infection, as defined by pragmatic broad criteria, than placebo. 
(Funded by the Medical Research Council and others; AIMS Current Controlled 
Trials number, ISRCTN97143849.)
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Globally, 208 million women and adolescents become pregnant each year,1 but 10 to 20% of pregnancies end in 
spontaneous abortion.2 In many of these cases, 
surgery is needed to remove retained products of 
conception3; such surgery is one of the most com-
mon gynecologic operations performed world-
wide. Infection is a serious potential conse-
quence of surgery to complete a spontaneous 
abortion, in particular in low- and middle-income 
countries.4 Pelvic infection can result in serious 
illness and death,5 as well as long-term conse-
quences from pelvic scarring, including in-
creased rates of ectopic pregnancy and infertility.6
Antibiotic prophylaxis before some operations 
has been shown to reduce the risk of postopera-
tive infections. A Cochrane review of 19 ran-
domized, controlled trials of the use of anti-
biotic prophylaxis before uterine evacuation for 
induced termination of pregnancy showed that 
prophylactic antibiotics reduced pelvic infection 
for this specific indication.7 However, for mis-
carriage surgery, evidence is lacking to show 
effectiveness,8 with four small, single-center stud-
ies showing no significant benefit from prophy-
lactic antibiotics. In addition to small size,4,9-11 
these studies had other methodologic limita-
tions, including inadequate antibiotic dose9 and 
poor adherence to the study protocol.4
International guidelines regarding antibiotic 
prophylaxis for surgery for incomplete sponta-
neous abortion are inconsistent. Some do not 
recommend antibiotics, reflecting the lack of 
evidence of efficacy,12-14 whereas others acknowl-
edge the lack of evidence but still advocate for 
their use on the basis of extrapolation of find-
ings from other indications.15
The question of whether to use prophylactic 
antibiotics is particularly important in low- and 
middle-income countries. Rates of surgery for in-
complete spontaneous abortion are high owing 
to low uptake of nonsurgical management ap-
proaches,16 a higher incidence of infections after 
surgery in these countries than in high-income 
countries,17-19 and poor access to resources to care 
for women in whom complications develop.20 
High-quality evidence is needed for rational anti-
microbial prescribing.21
We designed this international, parallel-group, 
double-blind, placebo-controlled, randomized trial 
(Antibiotics in Miscarriage Surgery [AIMS]) to 
investigate whether, among women and adoles-
cents undergoing surgery for incomplete sponta-
neous abortion, the use of presurgery prophylac-
tic antibiotics (oral doxycycline, 400 mg, and 
oral metronidazole, 400 mg) would reduce the 
risk of pelvic infection. The trial was conducted 
in four countries: Malawi, Pakistan, Tanzania, 
and Uganda.
Me thods
Trial Oversight
The AIMS trial was approved by ethical and 
regulatory bodies in each country and a United 
Kingdom ethics committee (reference number, 
LSTM13.15). Doxycycline and metronidazole 
were purchased from U.K. manufacturers, and 
the drugs were overencapsulated and packaged, 
alongside matched placebos, by Sharp Clinical 
Services UK. This company had no role in the 
design, conduct, analysis, or reporting of the trial.
Trial oversight was provided by an indepen-
dent trial steering committee and an independent 
data and safety monitoring committee, whose 
members reviewed accruing safety data during 
the period of recruitment. The trial was regis-
tered before commencement, and the protocol 
was published previously22 and is available with 
the full text of this article at NEJM.org. The first 
and last authors vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of the trial to the protocol.
Trial Patients
Women and adolescents were recruited from hos-
pitals in four countries: Malawi (three hospitals), 
Pakistan (five hospitals), Tanzania (three hospi-
tals), and Uganda (two hospitals). Patients were 
eligible for inclusion if they had received a diag-
nosis of a spontaneous abortion at less than 22 
weeks of gestation and were scheduled to under-
go surgical evacuation of the uterus. Exclusion 
criteria were evidence of induced abortion, evi-
dence of current pelvic infection, a need for im-
mediate surgery, current or recent (within 7 days) 
antibiotic use, an age younger than 16 years, or 
other contraindication to doxycycline or metro-
nidazole. A diagnosis of miscarriage was made 
by the clinician and confirmed on ultrasonogra-
phy if indicated. Surgery was performed accord-
ing to usual local practice.
Trial information was given in verbal and 
written formats in the local languages, and in-
A Quick Take 
is available at 
NEJM.org
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structions regarding follow-up care were also 
provided in pictorial form. Written informed 
consent was provided by all patients before ran-
domization and surgery.
Trial Design and Drug Regimen
Patients were randomly assigned in a 1:1 ratio to 
receive either doxycycline (400 mg, taken orally 
as four tablets) and metronidazole (400 mg, 
taken orally as one tablet) or five matched place-
bos, taken approximately 2 hours before surgery. 
The appearance, route, and administration of 
the assigned intervention were identical in the 
antibiotic-prophylaxis group and the placebo 
group.
Computerized randomization was performed 
centrally through a secure Internet facility, with 
the use of minimization to balance trial-group 
assignments according to the patient’s age (<35 
or ≥35 years), gestational age (<12 weeks, ≥12 
weeks, or unclear), type of miscarriage (incom-
plete or missed), and status with respect to hu-
man immunodeficiency virus (HIV) infection 
(known positive, known negative, or unknown). 
Patients, clinicians, and research staff were un-
aware of the trial-group assignments throughout 
the trial. Unblinding was permitted only in the 
event of a medical emergency.
Outcome Measures
The primary outcome was pelvic infection with-
in 14 days after miscarriage surgery. Diagnosis 
required the presence of two or more of four 
clinical features — purulent yellow, green, or 
foul-smelling vaginal discharge; pyrexia (>38.0°C 
according to ear thermometry); uterine, para-
metrial, or adnexal tenderness on examination; 
and a white-cell count of more than 12×109 per 
liter — or the presence of one of the clinical 
features in addition to the clinician’s judgment 
that antibiotics were needed for the treatment of 
pelvic infection.
At the start of the trial, pelvic infection was 
defined according to strict criteria, with diagno-
sis requiring two or more of the four clinical 
features above. These strict criteria are derived 
from Centers for Disease Control and Prevention 
(CDC) criteria and are consistent with current 
World Health Organization (WHO) guidelines.12,23,24 
However, during the conduct of the trial, it was 
observed by the examining clinicians that for 
some patients, only a single feature of infection 
was present, but the symptoms were of suffi-
cient severity that the clinicians judged that 
there was pelvic infection and that treatment 
was required. There was concern that the origi-
nal criteria, although highly specific, could lead 
to missed diagnoses in some patients with infec-
tion. This was potentially a patient safety issue, 
particularly where patient access to care was 
limited. Therefore, after discussion with the trial 
steering committee and the data and safety 
monitoring committee, it was decided that the 
diagnostic criteria by which pelvic infection was 
defined should be widened. The original strict 
definition of pelvic infection was reclassified as 
a secondary outcome. These changes were made 
before data were unblinded.
Other secondary outcomes were the compo-
nents of the initial primary outcome, additional 
antibiotic use, additional analgesia (in addition 
to standard postoperative analgesia), unplanned 
hospital admissions, unplanned consultations, 
the duration of symptoms, and the number of 
days before the patient returned to usual activi-
ties. Adverse events included maternal death, 
diarrhea, vomiting, allergy, anaphylaxis, serious 
adverse events, and blood transfusion.
Statistical Analysis
The planned sample size of 3400 patients was 
estimated to provide 90% power to detect a rela-
tive between-group difference of 40% in the risk 
of pelvic infection (risk ratio, 0.60)7 at a baseline 
risk of 7%, and 80% power at a baseline risk of 
5%, under the assumption of a two-sided P value 
of 0.05 and a lack of ascertainment of the pri-
mary outcome in 10%. All binary outcomes are 
presented as risk ratios produced from a log-
binomial regression model. Continuous measures 
were analyzed by means of linear regression and 
are presented as mean differences. All analyses 
were performed according to the intention-to-
treat principle and adjusted for the minimization 
variables unless model convergence did not oc-
cur, in which case unadjusted estimates were 
produced. Sensitivity analyses for the primary 
outcome include an unadjusted analysis, a per-
protocol analysis, and assessment of missing 
primary outcome data, under the assumption that 
all missing outcomes were pelvic infections and 
by means of a multiple-imputation approach.
Eight prespecified subgroup analyses were 
performed on the basis of maternal age (<35 or 
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≥35 years), gestational age (<12 weeks, ≥12 weeks, 
or unclear), status with respect to HIV infection 
(known positive, known negative, or unknown), 
miscarriage type (incomplete or missed), timing of 
antibiotic administration (<2 hours, 2 to 4 hours, 
or >4 hours before surgery), country (Malawi, 
Pakistan, Tanzania, or Uganda), patient residence 
(urban or rural), and type of miscarriage surgery 
(manual vacuum aspiration, suction curettage, 
or sharp curettage). These analyses were limited 
to the primary outcome only. The treatment ef-
fect within these subgroups was examined by 
the addition of the treatment-by-subgroup inter-
action measurement to the log-binomial regres-
sion model.
The analysis plan did not include correction 
for multiple comparisons when we conducted 
tests for secondary outcomes or subgroup analy-
sis. Results are therefore reported as point esti-
mates and 95% confidence intervals. The widths 
of the confidence intervals have not been ad-
justed for multiple comparisons, so the intervals 
should not be used to infer definitive treatment 
effects within subgroups or for secondary out-
comes. All analyses were generated with the use 
of SAS software, version 9.4 (SAS Institute).
R esult s
Trial Population
The trial-group assignments, loss to follow-up, 
and reasons for withdrawal are summarized in 
Figure 1. Of the 4098 women and adolescents 
who were assessed for eligibility, 3412 under-
went randomization from June 2014 through 
April 2017. A total of 1705 patients were as-
signed to antibiotic prophylaxis and 1707 to 
placebo. After withdrawals, 1700 patients in the 
antibiotic-prophylaxis group and 1704 in the 
placebo group were included in the intention-to-
treat analysis, with primary outcome data ob-
tained on 3360 (98.7%) of these patients.
The baseline characteristics were similar in 
the antibiotic-prophylaxis group and the placebo 
group (Table 1; and Table S1 in the Supplemen-
tary Appendix, available at NEJM.org). A major-
ity of the patients were educated to primary 
school level, obtained water from a shared tap or 
pump, and used a nonventilated pit latrine. 
Sharp curettage was used for the surgical proce-
dure in 70.0% of the patients, syringe-based 
suction (manual vacuum aspiration) in 23.2%, 
and suction curettage in 6.2%; the remaining 
0.6% of the patients did not undergo surgery.
Primary Outcome
The rate of pelvic infection was 4.1% in the anti-
biotic group (68 of 1676 pregnancies), as com-
pared with 5.3% (90 of 1684 pregnancies) in the 
placebo group (risk ratio, 0.77; 95% confidence 
interval [CI], 0.56 to 1.04; P = 0.09) (Table 2). The 
point estimates from prespecified sensitivity 
analyses were consistent with the point estimate 
from the primary analysis (Table S2 in the Sup-
plementary Appendix).
Secondary Outcomes
The rate of pelvic infection that was diagnosed 
according to the original strict definition was 
1.5% (26 of 1700 pregnancies) in the antibiotic-
prophylaxis group, as compared with 2.6% (44 
of 1704 pregnancies) in the placebo group (risk 
ratio, 0.60; 95% CI, 0.37 to 0.96). Fewer patients 
in the antibiotic-prophylaxis group than in the 
placebo group received additional analgesia (risk 
ratio, 0.72; 95% CI, 0.57 to 0.92) or had an un-
planned consultation (risk ratio, 0.60; 95% CI, 
0.37 to 0.97). Other prespecified secondary out-
comes, such as duration of pain or bleeding, did 
not differ substantially between the two groups 
(Table 2).
Subgroup Analyses
There were no significant interactions according 
to maternal age, gestational age at surgery, pres-
ence or absence of HIV infection, type of mis-
carriage, country of recruitment, time between 
administration of the trial intervention and the 
start of surgery, or residence in an urban or rural 
location (Table S3 in the Supplementary Appen-
dix). The only significant interaction suggesting a 
subgroup effect was for type of surgery (P = 0.02 
for interaction). The effect of prophylactic anti-
biotics on the risk of pelvic infection appeared 
greater in patients who underwent manual 
vacuum aspiration (rate of infection, 1.3% in the 
antibiotic-prophylaxis group and 4.1% in the 
placebo group; risk ratio, 0.32; 95% CI, 0.12 to 
0.86) than in those who underwent sharp curet-
tage (rate of infection, 5.3% in the antibiotic-
prophylaxis group and 6.0% in the placebo group; 
risk ratio, 0.89; 95% CI, 0.64 to 1.23); however, 
there was no correction made for the multiple 
comparisons.
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Figure 1. Enrollment, Randomization, Follow-up, and Outcomes.
Five patients who were assigned to receive antibiotic prophylaxis were not included in the intention‑to‑treat analysis: 
one who withdrew before receiving antibiotic prophylaxis, one who miscarried fully before surgery and then withdrew, 
and three who withdrew and did not undergo surgery. Three patients who were assigned to receive placebo were not 
included in the intention‑to‑treat analysis, all of whom withdrew and did not undergo surgery.
3412 Underwent randomization
4098 Women and adolescents were
assessed for eligibility
686 Were excluded
213 Declined to participate
60 Did not want to take medication
116 Did not want to attend follow-up
50 Had husband who declined
17 Had no reason given
230 Had other reason
1705 Were assigned to receive
antibiotic prophylaxis
1707 Were assigned to receive
placebo
24 Were excluded
23 Were lost to follow-up
1 Had telephone follow-up
with minimal data 
collected
20 Were excluded
18 Were lost to follow-up
2 Had telephone follow-up
with minimal data
collected
1702 Received antibiotic prophylaxis
707 Received antibiotic <2 hr before
surgery commenced
739 Received antibiotic 2–4 hr before
surgery commenced
247 Received antibiotic >4 hr before
surgery commenced
9 Did not undergo surgery
3 Did not receive antibiotic prophylaxis
2 Declined intervention
1 Withdrew
1702 Received placebo
708 Received placebo <2 hr before
surgery commenced
715 Received placebo 2–4 hr before
surgery commenced
270 Received placebo >4 hr before
surgery commenced
9 Did not undergo surgery
5 Did not receive placebo
3 Declined intervention
2 Had excessive bleeding and did
not wait for assigned intervention
1700 Were included in the intention-
to-treat analysis
1704 Were included in the intention-
to-treat analysis
1676 Were included in the primary
outcome analysis
1684 Were included in the primary
outcome analysis
1695 Underwent surgery
9 Did not undergo surgery
1 Was at hospital with water shortage
1 Miscarried fully before surgery
and withdrew
4 Miscarried fully before surgery
3 Withdrew
1698 Underwent surgery
9 Did not undergo surgery
1 Was in city affected by water issues
5 Miscarried fully before surgery
3 Withdrew
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Characteristic Antibiotic Prophylaxis (N = 1705) Placebo (N = 1707)
Age†
Distribution — no. (%)
<35 yr 1500 (88.0) 1505 (88.2)
≥35 yr 205 (12.0) 202 (11.8)
Mean — yr 26.2±6.6 26.0±6.6
Gestational age — no. (%)†
<12 wk 838 (49.1) 835 (48.9)
≥12 wk 866 (50.8) 871 (51.0)
Unclear 1 (0.1) 1 (0.1)
Type of miscarriage — no. (%)†
Incomplete 1429 (83.8) 1429 (83.7)
Missed 276 (16.2) 278 (16.3)
HIV status — no. (%)†
Known positive 33 (1.9) 34 (2.0)
Known negative 935 (54.8) 945 (55.4)
Unknown 737 (43.2) 728 (42.6)
Country — no. (%)
Malawi 1071 (62.8) 1074 (62.9)
Pakistan 177 (10.4) 176 (10.3)
Tanzania 110 (6.5) 100 (5.9)
Uganda 347 (20.4) 357 (20.9)
Time between administration of trial intervention 
and start of surgery
No. of patients evaluated 1693 1693
Median (IQR) — hr 2.2 (1.6–3.2) 2.2 (1.5–3.3)
Current residence — no. (%)
Rural 547 (32.1) 513 (30.1)
Urban 1158 (67.9) 1194 (69.9)
Type of surgery — no. (%)
Manual vacuum aspiration 394 (23.1) 397 (23.3)
Suction curettage 103 (6.0) 109 (6.4)
Sharp curettage 1198 (70.3) 1192 (69.8)
No surgery 10 (0.6) 9 (0.5)
Education — no. (%)
No formal education 67 (3.9) 48 (2.8)
Did not complete primary education 453 (26.6) 476 (27.9)
Completed primary education 589 (34.5) 618 (36.2)
Completed secondary education 370 (21.7) 346 (20.3)
Completed tertiary education 226 (13.3) 219 (12.8)
Latrine — no. (%)
No latrine 19 (1.1) 8 (0.5)
Nonventilated pit latrine 1191 (69.9) 1246 (73.0)
Ventilated improved pit latrine 181 (10.6) 178 (10.4)
Flush toilet 314 (18.4) 275 (16.1)
Water to wash in — no. (%)
Piped and tapped water 398 (23.3) 374 (21.9)
Shared tap or pump 1252 (73.4) 1269 (74.3)
Open water well 53 (3.1) 59 (3.5)
River, pond, or lake 2 (0.1) 5 (0.3)
*  Plus–minus values are means ±SD. There were no significant differences between the trial groups in any characteristic, 
except type of latrine (P = 0.04). Percentages may not total 100 because of rounding. IQR denotes interquartile range.
†  Shown are minimization variables.
Table 1. Characteristics of the Trial Patients at Baseline.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LIVERPOOL on March 21, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;11 nejm.org March 14, 20191018
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Adverse Events
There were no significant differences in the 
rates of diarrhea, vomiting, or blood transfusion 
between the antibiotic-prophylaxis group and the 
placebo group (Table 3). There were no cases of 
anaphylaxis reported and a single case of allergy 
in the antibiotic-prophylaxis group. One patient 
in the placebo group died 2 days after random-
ization and miscarriage surgery, subsequent to 
the surgical complication of uterine perforation 
with associated bowel injury. Serious adverse 
events were uncommon (16 [0.9%] in the anti-
biotic-prophylaxis group and 25 [1.5%] in the 
placebo group), and the incidence of such events 
did not differ significantly between the two groups.
Discussion
In this large, multicountry, multicenter, placebo-
controlled, randomized trial, we found that the 
use of prophylactic antibiotics before miscarriage 
surgery did not result in a significantly lower risk 
of pelvic infection than the use of placebo, when 
pelvic infection was defined pragmatically to 
incorporate clinicians’ judgment. In a secondary 
analysis that used strict criteria to define pelvic 
Outcome Antibiotic Prophylaxis Placebo
Risk Ratio or Difference 
in Means (95% CI)†
Primary outcome: pelvic infection defined by pragmatic broad criteria 
— no./total no. (%)‡
68/1676 (4.1) 90/1684 (5.3) 0.77 (0.56 to 1.04)§
≥2 Clinical features and antibiotics used to treat infection 24/1676 (1.4) 41/1684 (2.4)
≥2 Clinical features and no antibiotics used to treat infection 2/1676 (0.1) 3/1684 (0.2)
1 Clinical feature and need for antibiotics per clinician judgment 42/1676 (2.5) 46/1684 (2.7)
Secondary outcomes
Pelvic infection defined by strict criteria — no./total no. (%)¶ 26/1700 (1.5) 44/1704 (2.6) 0.60 (0.37 to 0.96)
Additional antibiotic use — no./total no. (%) 131/1676 (7.8) 164/1684 (9.7) 0.81 (0.65 to 1.01)
Additional analgesia — no./total no. (%) 106/1676 (6.3) 147/1684 (8.7) 0.72 (0.57 to 0.92)
Unplanned ward admission — no./total no. (%) 15/1676 (0.9) 21/1684 (1.2) 0.72 (0.37 to 1.39)
Unplanned consultation — no./total no. (%) 25/1700 (1.5) 42/1704 (2.5) 0.60 (0.37 to 0.97)
Abdominal or pelvic pain
Presence of abdominal or pelvic pain — no./total no. (%)‖ 210/1700 (12.4) 260/1704 (15.3) 0.80 (0.68 to 0.95)
Duration of abdominal or pelvic pain — days 2.9±3.0 2.6±2.8 0.3 (−0.2 to 0.8)
Vaginal bleeding
Presence of vaginal bleeding — no./total no. (%)‖ 448/1700 (26.4) 451/1704 (26.5) 1.00 (0.93 to 1.07)
Duration of vaginal bleeding — days 1.8±2.5 1.6±1.8 0.2 (−0.1 to 0.5)
Delay to usual activities
Occurrence of delay to usual activities — no./total no. (%)‖ 7/1671 (0.4) 10/1678 (0.6) 0.70 (0.27 to 1.84)
Duration of delay to usual activities — days 14.3±13.8 8.3±4.3 5.7 (−6.3 to 17.8)
*  Plus–minus values are means ±SD.
†  Risk ratios are presented for binary outcomes; values of less than 1 favor antibiotic prophylaxis. Differences in means are presented for 
 duration outcomes; values of less than 0 favor antibiotic prophylaxis. All estimates were adjusted for minimization variables when possible. 
Because the widths of the confidence intervals were not adjusted for multiple comparisons, they should not be used to infer definitive treat‑
ment differences.
‡  For the primary outcome analysis, pelvic infection was defined by the presence of two or more of four clinical features (purulent vaginal dis‑
charge, pyrexia, uterine tenderness, and leukocytosis) or by the presence of one of these features and the clinically identified need to admin‑
ister antibiotics.
§  P = 0.09. P values were not calculated for secondary outcomes.
¶  For the secondary outcome analysis, pelvic infection was defined by the presence of two or more of four clinical features: purulent vaginal 
discharge, pyrexia, uterine tenderness, and leukocytosis. Shown are the patients included in the intention‑to‑treat analysis.
‖  These outcomes were not prespecified.
Table 2. Primary, Secondary, and Other Outcomes.*
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infection, based on the CDC definition,23 we 
found that patients who received prophylactic 
antibiotics had a lower rate of pelvic infection 
than those who received placebo, but we did not 
adjust for multiple comparisons of secondary 
outcomes.
We chose the antibiotics used in this trial 
after careful consideration. In addition to their 
demonstrated effectiveness in treating pelvic 
infection, doxycycline and metronidazole are 
widely available internationally; both are included 
on the WHO model list of essential medicines25 
and are inexpensive and heat-stable. The oral 
route simplifies use, and administration of a 
single dose reduces issues of adherence that 
were identified previously,4 with doxycycline be-
ing particularly well suited to this approach ow-
ing to its long half-life. Allergy to either doxycy-
cline or metronidazole is very uncommon, which 
is vital if they are to be used widely for prophy-
laxis in resource-limited settings. No serious 
adverse reactions to these medications were re-
ported in our trial. There was concern that the 
use of doxycycline at a high dose before surgery 
might increase nausea and vomiting, but we 
found a similar frequency of these symptoms as 
well as other adverse effects in the active-treat-
ment group and the placebo group.
At the start of the trial, we defined pelvic 
infection using strict criteria based on CDC 
guidance,23 WHO guidance,12 a review of out-
comes in existing trials of pelvic infection, and 
consensus among the international investigator 
group. Diagnosis according to these strict crite-
ria has been common in the existing literature 
and is considered meaningful from the perspec-
tives of patients and policy makers. However, we 
widened the criteria that we used for diagnosis 
during the course of the trial, well before the 
unblinding of the data, in response to safety 
Adverse Event Antibiotic Prophylaxis Placebo Risk Ratio (95% CI)* P Value
Serious adverse event — no./total no. (%)† 16/1705 (0.9) 25/1707 (1.5) 0.64 (0.34–1.20) 0.16
Cause of serious adverse event — no.‡
Heavy bleeding 2 5
Bacterial meningitis and cerebral abscess 1 0
Ectopic pregnancy 3 2
Hysterectomy for myometritis 0 1
Hysterectomy for tubo‑ovarian abscess 1 0
Malaria 3 1
Pneumonia 0 1
Retained products of conception 6 12
Severe vomiting 0 1
Uterine perforation 0 2
Diarrhea — no./total no. (%) 21/1700 (1.2) 23/1704 (1.3) 0.92 (0.51–1.65) 0.77
Vomiting — no./total no. (%) 18/1700 (1.1) 15/1704 (0.9) 1.20 (0.61–2.38) 0.59
Allergy — no./total no. (%) 1/1700 (0.1) 0/1704 — —
Anaphylaxis — no./total no. (%) 0/1700 0/1704 — —
Death — no./total no. (%) 0/1677 1/1686 (0.1) — —
Blood transfusion — no./total no. (%) 1/1677 (0.1) 4/1686 (0.2) 0.25 (0.03–2.25) 0.17
*  Risk ratios of less than 1 favor antibiotic prophylaxis. All values were adjusted for minimization variables when possible.
†  An adverse event was classified as a serious adverse event if it resulted in death, was life‑threatening, resulted in hospi‑
talization or prolongation of existing hospitalization, resulted in persistent or clinically significant disability or incapacity, 
or consisted of a congenital anomaly or birth defect.
‡  Causes of serious adverse events were not prespecified outcomes.
Table 3. Adverse Events.
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concerns of some trial clinicians that some pel-
vic infections were being missed when the strict 
criteria were used. Whereas inclusion of clini-
cian judgment among the criteria for diagnosis 
would be expected to improve the sensitivity for 
identifying pelvic infection, it is also likely to 
have decreased specificity; it can be challenging 
to distinguish clinical findings that are part of 
the normal postoperative period or noninfective 
surgical complications from those indicating pel-
vic infection. The addition of clinician judgment 
to the pragmatic definition is likely to have diluted 
the observed treatment effect, with the change in 
criteria adding 42 events to the antibiotic-prophy-
laxis group and 46 events to the placebo group.
There has been little evidence to guide clini-
cal practice,8 with the existing trials evaluating 
antibiotic prophylaxis in patients undergoing mis-
carriage surgery limited by size and quality.4,9-11 
We identified four trials (involving a total of 869 
participants) of prophylactic antibiotic use in 
women undergoing surgery for miscarriage; these 
were all conducted at single centers and used 
different antibiotics and assessed different out-
comes. None of the four studies showed a signifi-
cant benefit, although they were not sufficiently 
powered to identify an important difference.
In conclusion, in this multicountry, multi-
center, double-blind, placebo-controlled, random-
ized trial conducted in low- and middle-income 
countries, we found that antibiotic prophylaxis 
with doxycycline and metronidazole before mis-
carriage surgery did not result in a significantly 
lower 14-day risk of pelvic infection, as defined 
by pragmatic broad criteria, than placebo. How-
ever, results suggested a possible benefit when 
pelvic infection was defined by strict criteria.
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